Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
Advanced Ovarian CancerImpact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of progression-free survival at 6 months in patients with platinum resistant advanced ovarian cancer.
Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer
Ovarian Cancer Stage IIICOvarian Cancer Stage IVM-Trap is an implantable medical device designed to capture disseminated tumor cells (DTCs). It is intended for use in advanced-stage ovarian cancer patients. The study objective is to assess the safety and the performance of the M-Trap device.
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in...
Platinum-resistant Epithelial Ovarian CancerThis is a phase I/II study to find the highest dose of hydroxychloroquine that can be given safely with itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer. The study will also determine the safety, tolerability, and initially determine whether the combination is useful in the treatment of patients with advanced platinum-resistant epithelial ovarian cancer.
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Ovarian CancerChiauranib may stop the growth of tumor cells by blocking Aurora kinase B(Aurora B)、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib(50mg,QD,PO) works in treating patients with relapsed or refractory ovarian cancer, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
Advanced Malignant Solid NeoplasmOvarian Carcinoma2 moreThis phase I trial studies the best dose and side effects of TAK-659 and paclitaxel in treating patients with advanced solid tumors. TAK-659 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TAK-659 and paclitaxel may work better in treating patients with advanced solid tumors.
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Biliary Tract Cancer (BTC)Colorectal Cancer (CRC)4 moreThe purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Ovary CancerCervix Cancer7 moreThe purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of...
Ovarian CancerThis is a longitudinal, national, open, multi-centre phase IV study which will recruit up to 141 patients with ovarian cancer in late relapse treated with niraparib according to the labelling In France.
Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer
Recurrent Ovarian CancerThe aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent ovarian cancer.
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant...
Recurrent Platinum Resistant Ovarian CancerThis is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.